| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 05/26/2009 | CA2225903C Aromatic diselenides and selenosulfides, their preparation and their uses, more particularly their therapeutical use |
| 05/26/2009 | CA2174325C Non-antigenic branched polymer conjugates |
| 05/26/2009 | CA2141022C Allergen of cladosporium herbarum |
| 05/26/2009 | CA2091102C Microsomal triglyceride transfer protein |
| 05/22/2009 | WO2009065098A1 Use of cathepsin k antagonists in the treatment of bone cancer |
| 05/22/2009 | WO2009065008A1 Skin treatment compositions |
| 05/22/2009 | WO2009065007A1 Modified il-4 mutein receptor antagonists |
| 05/22/2009 | WO2009065002A1 Method of administering conjugates |
| 05/22/2009 | WO2009064983A1 Methods and compositions for treating dry eye |
| 05/22/2009 | WO2009064838A1 Aqueous formulation of erythropoiesis stimulating protein stablised by antioxidants for parenteral administration |
| 05/22/2009 | WO2009064819A2 Compositions for the treatment of gastrointestinal inflammation |
| 05/22/2009 | WO2009064497A1 Prostatic acid phosphatase for the treatment of pain |
| 05/22/2009 | WO2009064437A1 Oriented protein films as a substrate for cell growth |
| 05/22/2009 | WO2009064421A1 Histone deacetylase inhibitors as skin lightening agents |
| 05/22/2009 | WO2009064300A1 Combinations of hdac inhibitors and cytokines/growth factors |
| 05/22/2009 | WO2009064298A1 Methods for treating obesity and obesity related diseases and disorders |
| 05/22/2009 | WO2009064051A1 Novel use of betaig-h3 fragment for preventing and treating rheumatoid |
| 05/22/2009 | WO2009063821A1 Heteroaryloxy quinazoline derivative |
| 05/22/2009 | WO2009063466A1 Compositions and methods for inhibiting hiv-1 replication and integrase activity |
| 05/22/2009 | WO2009063459A2 Synthetic peptide copolymers for treatment of neurodevelopmental disorders |
| 05/22/2009 | WO2009063241A1 3-hydroxyanthranilic acid or salts thereof1 for treating cancer or infections |
| 05/22/2009 | WO2009063221A2 Methods of treating or preventing inflammatory diseases of the intestinal tract |
| 05/22/2009 | WO2009063021A1 Pharmaceutical forms for the release of active compounds |
| 05/22/2009 | WO2009062914A2 Blood pressure lowering combination comprising ipp and/or vpp |
| 05/22/2009 | WO2009062898A1 New synthetic arginine substituted peptides and their use |
| 05/22/2009 | WO2009062750A2 Active soluble post-translationally modified neuregulin isoforms |
| 05/22/2009 | WO2009062399A1 Peptide ligand directed drug delivery |
| 05/22/2009 | WO2009062348A1 Methods for inhibiting influenza virus infection and their drugs |
| 05/22/2009 | WO2009062344A1 Use of lymphotoxin for sensitizing tumor cells to chemotherapeutic drugs |
| 05/22/2009 | WO2009062339A1 Methods of using interleukin-1 receptor antagonist as a myeloprotective agent |
| 05/22/2009 | WO2009062313A1 Composition containing granulocyte colony stimulating factor (gcsf) for hair growth |
| 05/22/2009 | WO2009062260A1 Therapy for multiple sclerosis |
| 05/22/2009 | WO2009062238A1 Epitope for neutralizing antibodies |
| 05/22/2009 | WO2009048945A8 Rapid mucosal gel or film insulin compositions |
| 05/22/2009 | WO2009046314A3 Moenomycin analogs, methods of synthesis, and uses thereof |
| 05/22/2009 | WO2009045900A3 Methods for treating or preventing diseases associated with low bone mass |
| 05/22/2009 | WO2009043507A3 Use of a peptide as a therapeutic agent |
| 05/22/2009 | WO2009043468A3 Use of corticotropin-releasing factor as a therapeutic agent |
| 05/22/2009 | WO2009040543A3 Bioactive peptide |
| 05/22/2009 | WO2009040087A3 Therapeutic use of peptide yglf and combination with kvlpvpq |
| 05/22/2009 | WO2009040073A3 Use of a peptide as a therapeutic agent |
| 05/22/2009 | WO2009040032A3 Use of a peptide as a therapeutic agent |
| 05/22/2009 | WO2009040025A3 Use of neuropeptide sf, alone or in combination with glp-2, as a therapeutic agent |
| 05/22/2009 | WO2009039969A3 Use of a vla-4 inhibitor tetrapeptide, alone or in combination with bpp-b, as a therapeutic agent |
| 05/22/2009 | WO2009034134A3 Use of natriuretic peptides for treating angioedema syndromes |
| 05/22/2009 | WO2009033822A3 Use of a combination of a cathepsin g fragment and teprotide as a therapeutic agent |
| 05/22/2009 | WO2009033812A3 Use of a combination of neuropeptide-ff and alpha-msh as a therapeutic agent |
| 05/22/2009 | WO2009033800A3 Use of a peptide as a therapeutic agent |
| 05/22/2009 | WO2009033771A3 Use of a peptide as a therapeutic agent |
| 05/22/2009 | WO2009033736A3 Use of met-enkephalin as a therapeutic agent |
| 05/22/2009 | WO2009033735A3 Use of melanin concentrating hormone and met-enkephalin as therapeutic agents |
| 05/22/2009 | WO2009033669A3 Use of the peptide his-ser-leu-gly-lys-trp-leu-gly-his-pro-asp-lys-phe alone or in combination with the peptide pro-gly-thr-cys-glu-ile-cys-ala-tyr-ala-ala-cys-thr-gly-cys-oh as a therapeutic agent |
| 05/22/2009 | WO2009028968A8 Cell marker of melanocyte cell lineage and uses thereof |
| 05/22/2009 | WO2009026112A3 Antimicrobial peptides |
| 05/22/2009 | WO2009016629A3 Pharmaceutical composition for treating wounds and related methods |
| 05/22/2009 | WO2009015087A3 Compositions and methods for treatment of trauma |
| 05/22/2009 | WO2008129180A3 Novel viii factors for the treatment of type a hemophilia |
| 05/22/2009 | WO2008100450A3 Therapeutic effects of bryostatins, bryologs, and other related substances on ischemia/stroke-induced memory impairment and brain injury |
| 05/22/2009 | WO2008100449A3 Therapeutic effects of bryostatins, bryologs, and other related substances on head trauma-induced memory impairment and brain injury |
| 05/22/2009 | WO2008068428A3 Cosmetic use of chitinase-type proteins<0} |
| 05/22/2009 | WO2008034133A3 Effect of tula on hiv |
| 05/22/2009 | WO2007058970A3 RECEPTOR ANTAGONIST AS THERAPEUTIC AGENTS FOR iNOS GENERATING ILLNESS |
| 05/22/2009 | WO2007000769A3 RECOMBINANT INTERFERON α2 (IFNα2) MUTANTS |
| 05/22/2009 | WO2006126188A3 Cxcr4 antagonists for wound healing and re-epithelialization |
| 05/22/2009 | WO2006117784A3 Pharmaceutical compositions comprising casein derived peptides and methods of use thereof |
| 05/22/2009 | WO2006105479A3 Immunomodulating compositions and methods for use in the treatment of human autoimmune diseases |
| 05/22/2009 | WO2006072954A3 Novel il-6 polynucleotides encoding variant il-6 polypeptides and methods using same |
| 05/22/2009 | CA2705862A1 Compositions and method for manipulating pim-1 activity in circulatory system cells |
| 05/22/2009 | CA2705810A1 Modified il-4 mutein receptor antagonists |
| 05/22/2009 | CA2705808A1 Method of administering conjugates |
| 05/22/2009 | CA2705708A1 Methods for treating obesity and obesity related diseases and disorders |
| 05/22/2009 | CA2705642A1 Methods of treating or preventing inflammatory diseases of the intestinal tract |
| 05/22/2009 | CA2705573A1 Skin lightening compositions comprising arbutin |
| 05/22/2009 | CA2705370A1 Heteroaryloxy quinazoline derivatives |
| 05/22/2009 | CA2705328A1 Active soluble post-translationally modified neuregulin isoforms |
| 05/22/2009 | CA2705289A1 Production of cytotoxic antibody-toxin fusion in eukaryotic algae |
| 05/22/2009 | CA2704957A1 Compositions for the treatment of gastrointestinal inflammation |
| 05/22/2009 | CA2703894A1 New synthetic arginine substituted peptides and their use |
| 05/22/2009 | CA2703814A1 Methods and compositions for treating dry eye |
| 05/21/2009 | US20090131949 delivering a bone substitue, water combinable combination of a calcium phosphate and a strontium phosphate and a salt of H3PO4; cement system for filling bone defects in a form-fit manner where the cement preparations are hardenable not only at room temperature, but also at body temperature; osteoporosis |
| 05/21/2009 | US20090131946 Devices and Methods for the Restoration of a Spinal Disc |
| 05/21/2009 | US20090131890 Protease inhibitors in absorbent articles |
| 05/21/2009 | US20090131857 Method and apparatus for introducing a medicinal dose directly into a mammalian patient's cerebrospinal fluid |
| 05/21/2009 | US20090131646 Novel bag proteins and nucleic acid molecules encoding them |
| 05/21/2009 | US20090131645 used to control the interaction of particular cell types with their external environment; for chronic pain; reduced side effects, long-lasting actions that do not require frequent injections or long-term catheterization; does not lead to tolerance and associated dependence |
| 05/21/2009 | US20090131534 Abuse-resistant amphetamine prodrugs |
| 05/21/2009 | US20090131533 Abuse-resistant amphetamine prodrugs |
| 05/21/2009 | US20090131526 Abuse-resistant amphetamine prodrugs |
| 05/21/2009 | US20090131525 Administering L-lysine-d-amphetamine or salts |
| 05/21/2009 | US20090131516 for treatment of attention deficit hyperactivity disorder, narcolepsy; bioavailability |
| 05/21/2009 | US20090131514 Buccal, polar and non-polar sprays containing propofol |
| 05/21/2009 | US20090131476 Abuse-resistant amphetamine prodrugs |
| 05/21/2009 | US20090131390 FK 228 derivates as HDAC inhibitors |
| 05/21/2009 | US20090131350 Hybrid Hepatocyte Growth Factor Gene Having High Expression Efficiency of Two Heterotypes of Hepatocyte Growth Factor |
| 05/21/2009 | US20090131337 Hair growth composition |
| 05/21/2009 | US20090131336 Isoxazole Derivatives and Use Thereof |
| 05/21/2009 | US20090131335 Abuse-resistant amphetamine prodrugs |
| 05/21/2009 | US20090131334 Abuse-resistant amphetamine prodrugs |
| 05/21/2009 | US20090131333 Abuse-resistant amphetamine prodrugs |
| 05/21/2009 | US20090131332 Abuse-resistant amphetamine prodrugs |